2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year